AstraZeneca Wins EU Approval for Enhertu Combination in First-Line Breast Cancer
AstraZeneca and Daiichi Sankyo said Enhertu plus pertuzumab was approved in the EU as first-line treatment for adults with unresectable or metastatic HER2-positive…
AstraZeneca and Daiichi Sankyo said Enhertu plus pertuzumab was approved in the EU as first-line treatment for adults with unresectable or metastatic HER2-positive…
Novartis said two Phase 3 REMODEL trials of remibrutinib met their primary endpoint, reducing the annualized relapse rate versus teriflunomide in relapsing multiple…
UCB said it will present 18 abstracts at the 16th European Epilepsy Congress in Athens from Sept. 5 to Sept. 9. A post…
Qiagen N.V. commercially launched QIAsymphony Connect, an IVD-compliant platform for automated clinical nucleic acid extraction. The new system aims to standardize extraction across…
Lonza appointed Samanta Cimitan as Chief Commercial Officer, the company said. Cimitan will join Lonza by January 1, 2027, in the newly created…
QIAGEN appointed Jonathan M. Pratt as its new Chief Executive Officer, effective September 1, 2026. Pratt brings over 25 years of leadership experience…
Sonova introduced its Phonak Audéo EON portfolio, featuring third-generation real-time AI hearing aids, the company said. The new EON Sphere models are 25%…
Fresenius agreed to sell approximately 7.8 million Fresenius Medical Care shares, equivalent to about 2.9% of the company’s issued share capital. The transaction…
Novartis plans to present 10 abstracts on its cardiovascular portfolio at the 2026 European Society of Cardiology (ESC) Congress. Late-breaking Phase 4 VICTORION-CHALLENGE…
dsm-firmenich’s Board of Directors proposed Richard Ridinger as its next Chairman. The company said current Chairman Thomas Leysen will retire after his successor…